Drug eluting stents: Developments and current status

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 703-712

  Khan, Wahid ^a   Farah, Shady ^a   Domb, Abraham J ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Angioplasty; Bare metal stent; Coronary artery disease; Drug eluting stent; Restenosis

Indexed keywords

ANGIOPLASTY; BARE-METAL STENT; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; RESTENOSIS;

ARTIFICIAL ORGANS; BLOOD VESSELS; DISEASES;

STENTS;

ANTIBODY; CHROMIUM; COBALT; DACTINOMYCIN; DEXAMETHASONE; EVEROLIMUS; METHACRYLIC ACID; PACLITAXEL; PLATINUM; POLYMER; RAPAMYCIN; STAINLESS STEEL; TACROLIMUS; UMIROLIMUS; ZOTAROLIMUS;

APOPTOSIS; BARE METAL STENT; BLOOD VESSEL INJURY; DRUG DESIGN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; MORTALITY; PRIORITY JOURNAL; REVIEW; STENT; STENT THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84862688034     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.02.010     Document Type: Review

References (104)

1. E. Deconinck, J. Sohier, I. De Scheerder, G. Van den Mooter, Pharmaceutical aspects of drug eluting stents, J. Pharm. Sci. 97 (12) (2008) 5047-5060.
2. D.M. Martin, F.J. Boyle, Drug-eluting stents for coronary artery disease: a review, Med. Eng. Phys. 33 (2) (2011) 148-163.
3. S.V. Rao, R.M. Califf, J.M. Kramer, E.D. Peterson, T.P. Gross, C.J. Pepine, D.O.Williams, D. Donohoe, R. Waksman, R. Mehran, M.W. Krucoff, Postmarket evaluation of breakthrough technologies, Am. Heart J. 156 (2) (2008) 201-208.
4. L.T. Newsome, M.A. Kutcher, R.L. Royster, Coronary artery stents: Part I. Evolution of percutaneous coronary intervention, Anesth. Analg. 107 (2) (2008) 552-569.
5. T. Hinohara, Percutaneous coronary intervention: current perspective, Keio J. Med. 50 (3) (2001) 152-160.
6. R. Erbel, T. Konorza, M. Haude, N. Dagres, D. Baumgart, Future of interventional cardiology in the treatment of coronary artery disease, Herz 27 (6) (2002) 471-480.
7. Y.K. Joung, H.I. Kim, S.S. Kim, K.H. Chung, Y.S. Jang, K.D. Park, Estrogen release from metallic stent surface for the prevention of restenosis, J. Control. Release 92 (1-2) (2003) 83-91.
8. I. Sheiban, G. Villata, M. Bollati, D. Sillano, M. Lotrionte, G. Biondi-Zoccai, Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V), Vasc. Health Risk Manag. 4 (1) (2008) 31-38.
9. M. Butt, D. Connolly, G.Y. Lip, Drug-eluting stents: a comprehensive appraisal, Future Cardiol. 5 (2) (2009) 141-157.
10. F. Alfonso, M.J. Perez-Vizcayno, A. Cruz, J. Garcia, P. Jimenez-Quevedo, J. Escaned, R. Hernandez, Treatment of patients with in-stent restenosis, EuroIntervention 5 (Suppl. D) (2009) D70-D78.
11. A.E. Alahmar, A.D. Grayson, M. Andron, M. Egred, E.D. Roberts, B. Patel, R.K. Moore, K. Albouaini, M. Jackson, R.A. Perry, Reduction in mortality and target-lesion revascularisation at 2 years: a comparison between drug-eluting stents and conventional bare-metal stents in the "real world", Int. J. Cardiol. 132 (3) (2009) 398-404.
12. S. McGinty, S. McKee, R.M. Wadsworth, C. McCormick, Modelling drug-eluting stents, Math. Med. Biol. 28 (1) (2011) 1-29.
13. J.J. Wykrzykowska, Y. Onuma, P.W. Serruys, Advances in stent drug delivery: the future is in bioabsorbable stents, Expert Opin. Drug Deliv. 6 (2) (2009) 113-126.
14. L. Mauri, T.S. Silbaugh, P. Garg, R.E. Wolf, K. Zelevinsky, A. Lovett, M.R. Varma, Z. Zhou, S.L. Normand, Drug-eluting or bare-metal stents for acute myocardial infarction, N. Engl. J. Med. 359 (13) (2008) 1330-1342.
15. A.J. Kirtane, A. Gupta, S. Iyengar, J.W. Moses, M.B. Leon, R. Applegate, B. Brodie, E. Hannan, K. Harjai, L.O. Jensen, S.J. Park, R. Perry, M. Racz, F. Saia, J.V. Tu, R. Waksman, A.J. Lansky, R. Mehran, G.W. Stone, Safety and efficacy of drugeluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies, Circulation 119 (25) (2009) 3198-3206.
16. J. Doostzadeh, L.N. Clark, S. Bezenek, W. Pierson, P.R. Sood, K. Sudhir, Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent, Coron. Artery Dis. 21 (1) (2010) 46-56.
17. M. Joner, G. Nakazawa, A.V. Finn, S.C. Quee, L. Coleman, E. Acampado, P.S. Wilson, K. Skorija, Q. Cheng, X. Xu, H.K. Gold, F.D. Kolodgie, R. Virmani, Endothelial cell recovery between comparator polymer-based drug-eluting stents, J. Am. Coll. Cardiol. 52 (5) (2008) 333-342.
18. R.A. Lange, L.D. Hillis, Second-generation drug-eluting coronary stents, N. Engl. J. Med. 362 (18) (2010) 1728-1730.
19. J.J. Lopez, M.J. Keyes, S. Nathan, R. Piana, M. Pencina, G. Dhar, S. Marso, S. Rao, S. Shammo, W. Marquardt, D.J. Cohen, N.S. Kleiman, Rapid adoption of drugeluting stents: clinical practices and outcomes from the early drug-eluting stent era, Am. Heart J. 160 (4) (2010) 767-774.
20. C.I. Stefanadis, Are all drug-eluting stents the same? Hellenic J. Cardiol. 52 (1) (2011) 96.
21. G. Mani, M.D. Feldman, D. Patel, C.M. Agrawal, Coronary stents: a materials perspective, Biomaterials 28 (9) (2007) 1689-1710.
22. J. Ako, H.N. Bonneau, Y. Honda, P.J. Fitzgerald, Design criteria for the ideal drug-eluting stent, Am. J. Cardiol. 100 (8B) (2007) 3M-9M.
23. F. Jung, R. Bach, R.P. Franke, Effect of crimping on the contamination of coronary stents, Eur. Heart J. 20 (8) (1999) 628.
24. P. Mortier, P.R. Verdonck, Stent design matters: insights from virtual bench testing, Expert. Rev. Cardiovasc. Ther. 8 (5) (2010) 613-615.
25. L.K. Pendyala, X. Yin, J. Li, J.P. Chen, N. Chronos, D. Hou, The first-generation drug-eluting stents and coronary endothelial dysfunction, JACC Cardiovasc. Interv. 2 (12) (2009) 1169-1177.
26. C. Mrowietz, R.P. Franke, U.T. Seyfert, J.W. Park, F. Jung, Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents, Clin. Hemorheol. Microcirc. 32 (2) (2005) 89-103.
27. K. Matschke, S.M. Tugtekin, U. Kappert, F. Jung, J.W. Park, M. Knaut, Do drug-eluting stents influence the spectrum of coronary artery bypass surgery? Herz 29 (2) (2004) 201-207.
28. Y. Levy, D. Mandler, J. Weinberger, A.J. Domb, Evaluation of drug-eluting stents' coating durability-clinical and regulatory implications, J. Biomed. Mater. Res. B Appl. Biomater. 91 (1) (2009) 441-451.
29. T. Parker, V. Dave, R. Falotico, Polymers for drug eluting stents, Curr. Pharm. Des. 16 (36) (2011) 3978-3988.
30. I.K. De Scheerder, K.L. Wilczek, E.V. Verbeken, J. Vandorpe, P.N. Lan, E. Schacht, H. De Geest, J. Piessens, Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries, Atherosclerosis 114 (1) (1995) 105-114.
31. Y. Levy, N. Tal, G. Tzemach, J. Weinberger, A.J. Domb, D. Mandler, Drug-eluting stent with improved durability and controllability properties, obtained via electrocoated adhesive promotion layer, J. Biomed. Mater. Res. B Appl. Biomater. 91 (2) (2009) 819-830.
32. J.E. Puskas, L.G. Munoz-Robledo, R.A. Hoerr, J. Foley, S.P. Schmidt, M. Evancho- Chapman, J. Dong, C. Frethem, G. Haugstad, Drug-eluting stent coatings, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1 (4) (2009) 451-462.
33. J.E. Moore Jr., Biomechanical issues in endovascular device design, J. Endovasc. Ther. 16 (Suppl 1) (2009) I1-I11.
34. S. Garg, P.W. Serruys, Coronary stents: looking forward, J. Am. Coll. Cardiol. 56 (10 Suppl.) (2010) S43-S78.
35. T. Pilgrim, L. Raber, A. Limacher, L. Loffel, P. Wenaweser, S. Cook, J.C. Stauffer, M. Togni, R. Vogel, A. Garachemani, A. Moschovitis, A.A. Khattab, C. Seiler, B. Meier, P. Juni, S. Windecker, Comparison of titanium-nitride-oxide- coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial, JACC Cardiovasc. Interv. 4 (6) (2011) 672-682.
36. D. Teomim, I. Fishbien, G. Golomb, L. Orloff, M. Mayberg, A.J. Domb, Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury, J. Control. Release 60 (1) (1999) 129-142.
37. C.A. Kavanagh, Y.A. Rochev, W.M. Gallagher, K.A. Dawson, A.K. Keenan, Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems, Pharmacol. Ther. 102 (1) (2004) 1-15.
38. E. Grube, U. Gerckens, R. Muller, L. Bullesfeld, Drug eluting stents: initial experiences, Z. Kardiol. 91 (Suppl. 3) (2002) 44-48.
39. G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg, J.J. Popma, M.E. Russell, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N. Engl. J. Med. 350 (3) (2004) 221-231.
40. B.L. van der Hoeven, N.M. Pires, H.M. Warda, P.V. Oemrawsingh, B.J. van Vlijmen, P.H. Quax, M.J. Schalij, E.E. van der Wall, J.W. Jukema, Drug-eluting stents: results, promises and problems, Int. J. Cardiol. 99 (1) (2005) 9-17.
41. C. Tamburino, D. Capodanno, Evolution of stents: past, present and future, Expert. Rev. Cardiovasc. Ther. 7 (5) (2009) 443-446.
42. S.E. Burke, R.E. Kuntz, L.B. Schwartz, Zotarolimus (ABT-578) eluting stents, Adv. Drug Deliv. Rev. 58 (3) (2006) 437-446.
43. C.M. Matter, I. Rozenberg, A. Jaschko, H. Greutert, D.J. Kurz, S. Wnendt, B. Kuttler, H. Joch, J. Grunenfelder, G. Zund, F.C. Tanner, T.F. Luscher, Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells, J. Cardiovasc. Pharmacol. 48 (6) (2006) 286-292.
44. J.J. Wykrzykowska, L. Raber, T. de Vries, M. Bressers, P. Buszman, A. Linke, T. Ischinger, V. Klauss, F. Eberli, R. Corti, W. Wijns, M.C. Morice, C. di Mario, E. Regar, P. Juni, S.Windecker, P.W. Serruys, Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy, EuroIntervention 5 (3) (2009) 310-317.
45. E. Grube, L. Buellesfeld, BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease, Expert Rev. Med. Devices 3 (6) (2006) 731-741.
46. P.W. Serruys, J.A. Ormiston, G. Sianos, J.E. Sousa, E. Grube, P. den Heijer, P. de Feyter, P. Buszman, A. Schomig, J. Marco, L. Polonski, L. Thuesen, A.M. Zeiher, J.H. Bett, M.J. Suttorp, H.D. Glogar, M. Pitney, G.T. Wilkins, R. Whitbourn, S. Veldhof, K. Miquel, R. Johnson, L. Coleman, R. Virmani, Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial, J. Am. Coll. Cardiol. 44 (7) (2004) 1363-1367.
47. P.W. Radke, C. Weber, A. Kaiser, A. Schober, R. Hoffmann, Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug? Curr. Pharm. Des. 10 (4) (2004) 349-355.
48. G. Pesarini, V. Ferrero, F. Tomai, L. Paloscia, N. De Cesare, C. Tamburino, F. Piscione, F. Vassanelli, F. Ribichini, Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry, J. Invasive Cardiol. 21 (3) (2009) 86-91.
49. R.K. Aggarwal, D.C. Ireland, M.A. Azrin, M.D. Ezekowitz, D.P. de Bono, A.H. Gershlick, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody, Circulation 94 (12) (1996) 3311-3317.
50. M. Miglionico, G. Patti, A. D'Ambrosio, G. Di Sciascio, Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients, Catheter. Cardiovasc. Interv. 71 (5) (2008) 600-604.
51. G. Nakazawa, J.F. Granada, C.L. Alviar, A. Tellez, G.L. Kaluza, M.Y. Guilhermier, S. Parker, S.M. Rowland, F.D. Kolodgie, M.B. Leon, R. Virmani, Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization, JACC Cardiovasc. Interv. 3 (1) (2010) 68-75.
52. C. Yang, H.M. Burt, Drug-eluting stents: factors governing local pharmacokinetics, Adv. Drug Deliv. Rev. 58 (3) (2006) 402-411.
53. G. Acharya, K. Park, Mechanisms of controlled drug release from drug-eluting stents, Adv. Drug Deliv. Rev. 58 (3) (2006) 387-401.
54. C.P. Naseerali, P.R. Hari, K. Sreenivasan, The release kinetics of drug eluting stents containing sirolimus as coated drug: role of release media, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 (7-8) (2010) 709-712.
55. A. Neubert, K. Sternberg, S. Nagel, C. Harder, K.P. Schmitz, H.K. Kroemer, W. Weitschies, Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents, J. Control. Release 130 (1) (2008) 2-8.
56. A. Seidlitz, S. Nagel, B. Semmling, N. Grabow, H. Martin, V. Senz, C. Harder, K. Sternberg, K.P. Schmitz, H.K. Kroemer, W. Weitschies, Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flowthrough cell, Eur. J. Pharm. Biopharm. 78 (1) (2011) 36-48.
57. C.J. Pan, J.J. Tang, Y.J. Weng, J. Wang, N. Huang, Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents, Colloids Surf. B Biointerfaces 73 (2) (2009) 199-206.
58. J. Mikkonen, I. Uurto, T. Isotalo, A. Kotsar, T.L. Tammela, M. Talja, J.P. Salenius, P. Tormala, M. Kellomaki, Drug-eluting bioabsorbable stents - an in vitro study, Acta Biomater. 5 (8) (2009) 2894-2900.
59. D.J. Kereiakes, Safety of drug-eluting stents, Rev. Cardiovasc. Med. 11 (4) (2010) 187-199 quiz 200.
60. G.W. Vetrovec, Drug eluting stents in AMI: keep the data coming, Catheter. Cardiovasc. Interv. 71 (6) (2008) 770-771.
61. A.J. Nordmann, M. Briel, H.C. Bucher, Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis, Eur. Heart J. 27 (23) (2006) 2784-2814.
62. D.W. Park, S.W. Park, K.H. Park, B.K. Lee, Y.H. Kim, C.W. Lee, M.K. Hong, J.J. Kim, S.J. Park, Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up, Am. J. Cardiol. 98 (3) (2006) 352-356.
63. A. Jeremias, A. Kirtane, Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention, Ann. Intern. Med. 148 (3) (2008) 234-238.
64. J.R. Costa Jr., A. Abizaid, R. Costa, F. Feres, L.F. Tanajura, G. Maldonado, R. Staico, D. Siqueira, A.G. Sousa, R. Bonan, J.E. Sousa, 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial, JACC Cardiovasc. Interv. 2 (5) (2009) 422-427.
65. A. Curcio, D. Torella, G. Cuda, C. Coppola, M.C. Faniello, F. Achille, V.G. Russo, M. Chiariello, C. Indolfi, Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis, Am. J. Physiol. Heart Circ. Physiol. 286 (3) (2004) H902-H908.
66. M.C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F.D. Kolodgie, H.K. Gold, R. Virmani, A.V. Finn, Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents, JACC Cardiovasc. Interv. 1 (5) (2008) 535-544.
67. A.B. Schoenkerman, R.J. Lundstrom, Coronary stent infections: a case series, Catheter. Cardiovasc. Interv. 73 (1) (2009) 74-76.
68. S.K. James, U. Stenestrand, J. Lindback, J. Carlsson, F. Schersten, T. Nilsson, L. Wallentin, B. Lagerqvist, Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden, N. Engl. J. Med. 360 (19) (2009) 1933-1945.
69. M. Vorpahl, R. Virmani, E. Ladich, A.V. Finn, Vascular remodeling after coronary stent implantation, Minerva Cardioangiol. 57 (5) (2009) 621-628.
70. M.W. Webster, J.A. Ormiston, Drug-eluting stents and late stent thrombosis, Lancet 370 (9591) (2007) 914-915.
71. K. Steigerwald, S. Merl, A. Kastrati, A. Wieczorek, M. Vorpahl, R. Mannhold, M. Vogeser, J. Hausleiter, M. Joner, A. Schomig, R. Wessely, The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts, Biomaterials 30 (4) (2009) 632-637.
72. M. Prunotto, C. Vignolini, V. Lolli, A. Black, S. Gaggianesi, A. Santarelli, M. Galloni, Short-, mid-, and long-term effects of a polymer-free tacrolimus-eluting stent in a porcine coronary model, J. Biomed. Mater. Res. A 88 (4) (2009) 872-879.
73. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S.H. Su, J. Shulze, S. Kar, Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model, Circ. Cardiovasc. Interv. 3 (2) (2010) 174-183.
74. Y. Levi, A.J. Domb, N. Amir, N. Eliyahu, U. Cohn, N. Tal, Crystaline drug-containing coatings, WO Patent 2010086863 (A2), 20100508, 2010.
75. C. Di Mario, G. Ferrante, Biodegradable drug-eluting stents: promises and pitfalls, Lancet 371 (9616) (2008) 873-874.
76. S. Garg, P. Serruys, Biodegradable stents and non-biodegradable stents, Minerva Cardioangiol. 57 (5) (2009) 537-565.
77. S. Ramcharitar, P.W. Serruys, Fully biodegradable coronary stents: progress to date, Am. J. Cardiovasc. Drugs 8 (5) (2008) 305-314.
78. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. Motohara, H. Uehata, Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans, Circulation 102 (4) (2000) 399-404.
79. J.A. Ormiston, P.W. Serruys, E. Regar, D. Dudek, L. Thuesen, M.W. Webster, Y. Onuma, H.M. Garcia-Garcia, R. McGreevy, S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet 371 (9616) (2008) 899-907.
80. J.A. Ormiston, P.W. Serruys, Bioabsorbable coronary stents, Circ. Cardiovasc. Interv. 2 (3) (2009) 255-260.
81. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F.R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T.F. Luscher, N. Weissman, R. Waksman, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial, Lancet 369 (9576) (2007) 1869-1875.
82. A.K. Jain, C. Lotan, I.T. Meredith, F. Feres, R. Zambahari, N. Sinha, M.T. Rothman, Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry, Heart 96 (11) (2010) 848-853.
83. G. Guagliumi, H. Ikejima, V. Sirbu, H. Bezerra, G. Musumeci, N. Lortkipanidze, L. Fiocca, S. Tahara, A. Vassileva, A. Matiashvili, O. Valsecchi, M. Costa, Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT Study (Optical Coherence Tomography in Long Lesions), JACC Cardiovasc. Interv. 4 (7) (2011) 778-785.
84. M.W. Basalus, K. Tandjung, K.G. van Houwelingen, M.G. Stoel, F.H. de Man, J.W. Louwerenburg, S.A. Said, G.C. Linssen, M.A. Kleijne, J. van der Palen, J. Huisman, P.M. Verhorst, C. von Birgelen, TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives, Neth. Heart J. 18 (7-8) (2010) 360-364.
85. B. Chevalier, C. Di Mario, F.J. Neumann, F. Ribichini, P. Urban, J.J. Popma, P.J. Fitzgerald, D.E. Cutlip, D.O. Williams, J. Ormiston, E. Grube, R. Whitbourn, L.B. Schwartz, A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: the ZoMaxx I trial, JACC Cardiovasc. Interv. 1 (5) (2008) 524-532.
86. K. Waseda, T. Hasegawa, J. Ako, Y. Honda, E. Grube, R. Whitbourn, J. Ormiston, C.D. O'Shaughnessy, T.D. Henry, P. Overlie, L.B. Schwartz, K. Sudhir, B. Chevalier, W.A. Gray, A.C. Yeung, P.J. Fitzgerald, Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials, Circ. J. 74 (11) (2010) 2334-2339.
87. K. Waseda, J. Ako, M. Yamasaki, T. Koizumi, R. Sakurai, Y. Hongo, B.K. Koo, J. Ormiston, S.G. Worthley, R.J. Whitbourn, D.L. Walters, I.T. Meredith, P.J. Fitzgerald, Y. Honda, Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE, trial. Circ. Cardiovasc. Interv. 4 (3) (2011) 248-255.
88. D.J. Kereiakes, L.A. Cannon, J.A. Ormiston, M.A. Turco, T. Mann, G.J. Mishkel, T. McGarry, H. Wang, P. Underwood, K.D. Dawkins, Propensity-matched patientlevel comparison of the TAXUS Liberte and TAXUS Element (ION) paclitaxeleluting stents, Am. J. Cardiol. 108 (6) (2011) 828-837.
89. S. Verheye, P. Agostoni, C.L. Dubois, J. Dens, J. Ormiston, S. Worthley, B. Trauthen, T. Hasegawa, B.K. Koo, P.J. Fitzgerald, R. Mehran, A.J. Lansky, 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study, J. Am. Coll. Cardiol. 53 (12) (2009) 1031-1039.
90. P.R. Stella, R. Mueller, G. Pavlakis, B. De Bruyne, K. Hauptmann, M.C. Morice, B. Chevalier, J. Fajadet, H. Sievert, E. Grube, One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial, EuroIntervention 4 (2) (2008) 200-207.
91. E. Grube, H. Sievert, K.E. Hauptmann, R. Mueller, U. Gerckens, L. Buellesfeld, J. Ako, T. Shimohama, M. Costa, P. Fitzgerald, Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results, EuroIntervention 4 (1) (2008) 71-76.
92. Z. Gao, Y.J. Yang, J.L. Chen, S.B. Qiao, B. Xu, X.W. Qin, M. Yao, H.B. Liu, Y.J. Wu, J.Q. Yuan, J. Chen, S.J. You, J.J. Li, R.L. Gao, Outcome of patients implanted with bioabsorbable polymer sirolimus-eluting stent (Excel) and the durable polymer sirolimus-eluting stent (Cypher), Zhonghua Xin Xue Guan Bing Za Zhi 36 (12) (2008) 1074-1077.
93. J. Ge, J. Qian, X. Wang, Q. Wang, W. Yan, Y. Yan, B. Fan, L. Ge, X. Liu, Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries, Catheter. Cardiovasc. Interv. 69 (2) (2007) 198-202.
94. G.B. Danzi, B. Chevalier, M. Ostojic, M. Hamilos,W. Wijns, Nobori drug eluting stent system: clinical evidence update, Minerva Cardioangiol. 58 (5) (2010) 599-610.
95. J.R. Costa Jr., A. Abizaid, F. Feres, R. Costa, A.C. Seixas, F. Maia, L.F. Tanajura, R. Staico, D. Siqueira, L. Meredith, V. Bhat, J. Yan, J. Ormiston, A.G. Sousa, P. Fitzgerald, J.E. Sousa, EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions, EuroIntervention 4 (1) (2008) 53-58.
96. P.W. Serruys, S. Garg, A. Abizaid, J. Ormiston, S. Windecker, S. Verheye, C. Dubois, J. Stewart, K.E. Hauptmann, J. Schofer, K. Stangl, B. Witzenbichler, M. Wiemer, E. Barbato, T. de Vries, A.M. den Drijver, H. Otake, L. Meredith, S. Toyloy, P. Fitzgerald, A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study, EuroIntervention 6 (2) (2010) 195-205.
97. P.A. Davlouros, G. Nikokiris, V. Karantalis, E. Mavronasiou, I. Xanthopoulou, A. Damelou, G. Tsigkas, D. Alexopoulos, Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: an optical coherence tomography study, Int. J. Cardiol. 151 (2) (2010) 155-159.
98. G. Guagliumi, V. Sirbu, G. Musumeci, H.G. Bezerra, A. Aprile, H. Kyono, L. Fiocca, A. Matiashvili, N. Lortkipanidze, A. Vassilev, J.J. Popma, D.J. Allocco, K.D. Dawkins, O. Valsecchi, M.A. Costa, Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI), Circ. Cardiovasc. Interv. 3 (4) (2010) 367-375.
99. E. Grube, J. Schofer, K.E. Hauptmann, G. Nickenig, N. Curzen, D.J. Allocco, K.D. Dawkins, A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent, JACC Cardiovasc. Interv. 3 (4) (2010) 431-438.
100. N. Reifart, K.E. Hauptmann, A. Rabe, D. Enayat, K. Giokoglu, Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial, EuroIntervention 6 (3) (2010) 356-360.
101. G.G. Biondi-Zoccai, C. Moretti, M. Lotrionte, I. Sheiban, Safety of drug-coated stents, Expert Opin. Drug Saf. 7 (5) (2008) 597-606.
102. J.R. Costa Jr., A. Abizaid, R. Costa, F. Feres, L.F. Tanajura, L.A. Mattos, R. Staico, D. Siqueira, A.G. Sousa, R. Bonan, J.E. Sousa, Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system, JACC Cardiovasc. Interv. 1 (5) (2008) 545-551.
103. J. Mehilli, A. Kastrati, R. Wessely, A. Dibra, J. Hausleiter, B. Jaschke, J. Dirschinger, A. Schomig, Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss, Circulation 113 (2) (2006) 273-279.
104. R. Erbel, D. Bose, M. Haude, I. Kordish, S. Churzidze, N. Malyar, T. Konorza, S. Sack, Absorbable coronary stents. New promising technology, Herz 32 (4) (2007) 308-319.